Category Research

Biotech

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a pioneering company in the development of next-generation therapies for age-associated diseases, has officially launched its first-in-human clinical trial for MIB-725, a novel investigational…

Read MoreMetro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725
Glycomine

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG Glycomine, Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapies for patients suffering from orphan and underserved diseases, has announced the successful closure of a…

Read MoreGlycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG
Octave

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions In a significant advancement for the field of neurodegenerative disease management, Octave Bioscience, Inc., a precision care company focused on transforming how multiple sclerosis (MS) and other…

Read MoreOctave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions
Eyestem

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial Bangalore-based biotech firm Eyestem Research has reported highly encouraging results from its Phase 1 clinical trial evaluating Eyecyte-RPE™, a novel investigational cell therapy aimed at treating geographic atrophy (GA) secondary…

Read MoreEyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial
Pill Penalty

New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs

New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation Reduction Act (IRA) on the U.S. biopharmaceutical sector—particularly in the…

Read MoreNew Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs
Exicure

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced a significant milestone today in its ongoing Phase 2 clinical…

Read MoreExicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment
Exicure

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet medical needs, announced significant updates today regarding its lead investigational…

Read MoreExicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)